PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
- Study Identifier: 826672
Recruitment StatusEnrolling By Invitation
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com